O. Usmani (London, United Kingdom), H. Chrystyn (Huddersfield, United Kingdom)
Peak inspiratory flow rates in COPD patients with Easyhaler® dry powder inhaler
L. P. Malmberg, P. Rytilä, P. Happonen, M. Härkönen, U. Rastas, T. Haahtela (Helsinki, Espoo, Finland)
|   |
In vitro evaluation of a novel ventilation chamber (VC) for delivery of aerosolized medication to the mechanically ventilated premature infant
M. Nagel, M. Foley, J. Mitchell, R. Ali, H. MacKay, D. Coppolo (London, Canada; Syracuse, United States Of America)
| |
Substantial in vitro equivalence exists for non-conducting (NC) and anti-static (AS) valved holding chambers (VHCs) provided pre-conditioning of the non-conducting VHC is undertaken
J. Mitchell, V. Avvakoumova, H. MacKay, R. Ali, M. Nagel (London, Canada)
| |
Dose emission from a formoterol aerolizer is dependent on inhalation flow and volume
S. Alaboud, K. Assi, H. Chrystyn (Bradford, Huddersfield, United Kingdom)
| |
A double-blind, single dose, four period, crossover study to demonstrate the equivalence between the two HFA formulations of formoterol fumarate; using serial spirometry measurements for 12 hrs
M. Mangale, P. A. Mahesh, S. Balamurugan, J. Po, J. Yewale, N. Sharma, S. Chachad, A. Sule, S. Purandare, A. Lulla (Mumbai, Mysore, Chennai, India)
| |
Additional benefits of beclomethasone/formoterol extrafine combination treatment on small airways function in asthma
N. Scichilone, S. Battaglia, C. Sorino, G. Paglino, L. Martino, G. Nicolini, V. Bellia (Palermo, Parma, Italy)
| |
The genuair® inhaler: a novel multidose dry powder inhaler for the delivery of various types of inhalation powder
R. Greguletz, M. Arlt, S. Anke, B. Fyrnys, J. Goede, A. Haaije de Boer, H. Frijlink (Bad Homburg, Germany; Groningen, Netherlands)
| |
Comparison of systemic pharmacodynamic effects of two HFA formulations of formoterol fumarate delivered by pressurised metered dose inhaler in healthy subjects
S. SubhashChandran, N. Syed, A. Jakkanwar, J. Yewale, S. Bommera, J. Po, S. Chahad, S. Purandare, A. Lulla, A. Sule (Mumbai, India)
| |
The genuair® inhaler, a novel multidose dry powder inhaler, demonstrates consistent aerodynamic precision
R. Greguletz, B. Fyrnys, J. Goede, A. Haaije de Boer, H. Frijlink (Bad Homburg, Germany; Groningen, Netherlands)
| |
A visual indicator for inhalation from a valved holding chamber (VHC) is an aid in delivery of inhaled medication to infants and small children via facemask
J. Mitchell, C. Doyle, R. Ali, V. Avvakoumova, M. Nagel, R. Sharpe (London, Canada)
| |
New anti-static youth valved holding chamber (VHC) can be used out-of-package and deliver β2-agonist medication effectively
J. Mitchell, V. Avvakoumova, H. MacKay, R. Ali, M. Nagel, R. Sharpe (London, Canada; Nottingham, United Kingdom)
| |
Inhalation characteristics of asthmatic children (child), adults asthmatics (adult) and chronic obstructive pulmonary disease patients when they inhale through a spiromax dry powder inhaler (DPI)
W. Ammari, P. Chetcuti, H. Hosker, D. Saralaya, H. Chrystyn (Bradford, Leeds, Keighley, Huddersfield, United Kingdom)
| |
Non-conducting valved holding chamber (VHC) delivers comparable medication to antistatic metal VHC when manufacturer instructions to precondition are followed
J. Mitchell, V. Avvakoumova, M. Nagel, R. Sharpe (London, Canada; Nottingham, United Kingdom)
| |
Comparison of valved-holding chamber (VHC)-facemask/mouthpiece with small volume nebulizer-facemask (SVN-F) for bronchodilator delivery
M. Hart, E. Abmas, R. Boehm, G. Hernandez, M. Millard (Dallas, United States Of America)
| |
Clinical equivalence of two HFA formulations of salmeterol xinafoate in asthmatic patients using 12 hour serial spirometry
N. Syed, S. Balamurgan, P. A. Mahesh, C. J. Po, A. Jakkanwar, N. Sharma, S. Chachad, S. Purandare, A. Sule, A. Lulla (Mumbai, Chennai, Mysore, India)
| |
In vitro characterisation of a novel electronic nebulizer utilising a customised single dose bfs-vial to improve handling and delivery performance
T. Gallem, M. Tservistas, M. Uhlig, E. Bitterle, S. Seemann, M. Knoch, M. Keller (Munich, Germany)
| |
Comparison of efficacy and safety of two HFA formulations of fluticasone propionate; a double-blind, randomised, multicentric, parallel group study in patients with persistent moderate asthma
M. Mangale, B. Singh, A. Mesquita, V. Saini, V. Prabhudesai, R. Premanand, J. Po, S. Chachad, A. Sule, S. Purandare, A. Lulla (Lucknow, Goa, Chandigarh, Tirupati, Mumbai, India)
| |
Sealed system helium-oxygen administration: is there a practical answer?
T. Standley, B. Jacobsen, P. Lambert (Cambridge, Guildford, United Kingdom)
| |
Comparison of systemic bioavailability of two formulations of budesonide nebulized suspension in healthy subjects
A. Jakkanwar, N. Syed, J. Po, S. Chachad, A. Sule, S. Purandare, A. Lulla (Mumbai, India)
| |
Characterisation of paranasal drug delivery devices in a human nasal cast model – do in vitro data support promises?
U. Schuschnig, A. Krüner, M. Keller ()
| |